螺内酯与依普利酮治疗肝硬化腹水的比较研究。,European Journal of Gastroenterology & Hepatology

当前位置： X-MOL 学术 › Eur. Gastroenterol. Hepatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

螺内酯与依普利酮治疗肝硬化腹水的比较研究。
European Journal of Gastroenterology & Hepatology ( IF 2.3 ) Pub Date : 2020-04-01 , DOI: 10.1097/meg.0000000000001678
Rishabh Sehgal ₁ , Harsimranjit Singh ₂ , Inder Pal Singh ₃

Affiliation

引言本研究旨在比较螺内酯和依普利酮治疗肝硬化腹水的疗效和副作用。材料与方法 105 名肝硬化腹水患者随机分为三组，每组 35 名。第 I 组服用螺内酯 100 mg，第 II 组服用依普利酮 100 mg，第 III 组服用依普利酮 50 mg。所有患者均进行限盐饮食（钠含量小于或等于 2 克）且未使用袢利尿剂。从基线开始 7 天后对患者进行随访，然后在三个月内每两周一次，并连续测量体重、腹围和副作用的发生率，尤其是男性乳房发育症、乳腺痛、高钾血症。结果进行了比较。Child-Turcotte-Pugh 评分为 C、大量腹水、排除肝性脑病、肝肾综合征和心、肾、恶性原因引起的腹水。观察组 I 和组 II 平均体重减轻的差异不显着（P = 0.964），而在组 I 和 III 之间进行比较时差异显着；和组 II 和 III（分别为 P = <0.001、<0.001）。在 I 组中，男性乳房发育的发生率为 14.28%，而在组 II 和组 III 中未观察到男性乳房发育病例（P <0.001，<0.001）。组 I 中的一名患者 (2.8%) 出现高钾血症，而组 II 和组 III 中没有患者出现高钾血症 (P = >0.05, >0.05)。结论依普利酮和螺内酯在治疗肝硬化腹水方面同样有效，但依普利酮评分的副作用超过螺内酯。

"点击查看英文标题和摘要"

Comparative study of spironolactone and eplerenone in management of ascites in patients of cirrhosis of liver.

INTRODUCTION The present study was conducted to compare the efficacy and side effects of Spironolactone and Eplerenone in management of ascites due to liver cirrhosis. MATERIALS AND METHODS 105 patients of ascites with liver cirrhosis were randomized into three groups of 35 patients each. Group I was given Spironolactone 100 mg, group II was given Eplerenone 100 mg and group III was given Eplerenone 50 mg. All patients were put on salt-restricted diet (less than or equal to 2 g of sodium) and no loop diuretics were used. Patients were followed after 7 days from the baseline and then biweekly for the period of three months and serial measurements of weight, abdominal girth and incidence of side effects especially gynecomastia, mastalgia, hyperkalemia were recorded. Results were compared. Patients having Child-Turcotte-Pugh score-C, massive ascites, hepatic encephalopathy, Hepatorenal syndrome and ascites due to cardiac, renal, malignant causes were excluded. OBSERVATIONS Difference in mean weight reduction was non significant (P = 0.964) in group I and group II whereas the difference was significant when comparison was made between Group I and III; and Group II and III (P = <0.001, <0.001, respectively). In group I, the incidence of gynecomastia was 14.28% whereas in group II and group III no case of gynecomastia was observed (P <0.001, <0.001). Hyperkalemia was present in one patient (2.8%) in group I whereas no patient developed hyperkalemia in group II and group III (P = >0.05, >0.05). CONCLUSION Eplerenone and spironolactone are equally effective in management of ascites due to liver cirrhosis but side effect profile of eplerenone scores over Spironolactone.

更新日期：2020-02-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南